发明名称 |
Low affinity FCGR deficient mice |
摘要 |
Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a deletion of the endogenous low affinity FcγR locus, and wherein the mouse is capable of expressing a functional FcRγ-chain. Genetically modified mice are described, including mice that express low affinity human FcγR genes from the endogenous FcγR locus, and wherein the mice comprise a functional FcRγ-chain. Genetically modified mice that express up to five low affinity human FcγR genes on accessory cells of the host immune system are provided. |
申请公布号 |
US9089599(B2) |
申请公布日期 |
2015.07.28 |
申请号 |
US201414152106 |
申请日期 |
2014.01.10 |
申请人 |
Regeneron Pharmaceuticals, Inc. |
发明人 |
Macdonald Lynn;Tu Naxin;Gurer Cagan;Stevens Sean;Murphy Andrew J. |
分类号 |
A61K49/00;A01K67/027;C07K14/735;G01N33/50 |
主分类号 |
A61K49/00 |
代理机构 |
Foley Hoag LLP |
代理人 |
Jones Brendan T.;Miyamoto Neil;Foley Hoag LLP |
主权项 |
1. A transgenic mouse whose genome comprises a homozygous disruption in an endogenous FcγRIIB α-chain gene, a homozygous disruption in an endogenous FcγRIV α-chain gene, a homozygous disruption in an endogenous FcγRIII α-chain gene, and a nucleic acid sequence encoding a human CD20 gene, wherein the mouse specifically expresses functional CD20 on B cells. |
地址 |
Tarrytown NY US |